Product Code: ETC6745643 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 China Intratumoral Cancer Therapies Market Overview |
3.1 China Country Macro Economic Indicators |
3.2 China Intratumoral Cancer Therapies Market Revenues & Volume, 2021 & 2031F |
3.3 China Intratumoral Cancer Therapies Market - Industry Life Cycle |
3.4 China Intratumoral Cancer Therapies Market - Porter's Five Forces |
3.5 China Intratumoral Cancer Therapies Market Revenues & Volume Share, By Technology, 2021 & 2031F |
3.6 China Intratumoral Cancer Therapies Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.7 China Intratumoral Cancer Therapies Market Revenues & Volume Share, By End-users, 2021 & 2031F |
4 China Intratumoral Cancer Therapies Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing incidence of cancer cases in China |
4.2.2 Growing awareness and acceptance of intratumoral therapies as an effective treatment option |
4.2.3 Technological advancements in intratumoral cancer therapies |
4.3 Market Restraints |
4.3.1 Stringent regulatory approval process for new therapies |
4.3.2 High costs associated with intratumoral cancer therapies |
4.3.3 Limited accessibility to advanced healthcare facilities in certain regions of China |
5 China Intratumoral Cancer Therapies Market Trends |
6 China Intratumoral Cancer Therapies Market, By Types |
6.1 China Intratumoral Cancer Therapies Market, By Technology |
6.1.1 Overview and Analysis |
6.1.2 China Intratumoral Cancer Therapies Market Revenues & Volume, By Technology, 2021- 2031F |
6.1.3 China Intratumoral Cancer Therapies Market Revenues & Volume, By Monoclonal Antibodies, 2021- 2031F |
6.1.4 China Intratumoral Cancer Therapies Market Revenues & Volume, By Vaccines, 2021- 2031F |
6.1.5 China Intratumoral Cancer Therapies Market Revenues & Volume, By Checkpoint Inhibitors, 2021- 2031F |
6.1.6 China Intratumoral Cancer Therapies Market Revenues & Volume, By Cell Therapies, 2021- 2031F |
6.1.7 China Intratumoral Cancer Therapies Market Revenues & Volume, By Immune System Modulators, 2021- 2031F |
6.1.8 China Intratumoral Cancer Therapies Market Revenues & Volume, By Adoptive Cell Transfer, 2021- 2031F |
6.2 China Intratumoral Cancer Therapies Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 China Intratumoral Cancer Therapies Market Revenues & Volume, By Lung Cancer, 2021- 2031F |
6.2.3 China Intratumoral Cancer Therapies Market Revenues & Volume, By Breast Cancer, 2021- 2031F |
6.2.4 China Intratumoral Cancer Therapies Market Revenues & Volume, By Melanoma, 2021- 2031F |
6.2.5 China Intratumoral Cancer Therapies Market Revenues & Volume, By Prostate Cancer, 2021- 2031F |
6.2.6 China Intratumoral Cancer Therapies Market Revenues & Volume, By Head & Neck Cancer, 2021- 2031F |
6.2.7 China Intratumoral Cancer Therapies Market Revenues & Volume, By Others, 2021- 2031F |
6.3 China Intratumoral Cancer Therapies Market, By End-users |
6.3.1 Overview and Analysis |
6.3.2 China Intratumoral Cancer Therapies Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.3.3 China Intratumoral Cancer Therapies Market Revenues & Volume, By Cancer Research Centres, 2021- 2031F |
6.3.4 China Intratumoral Cancer Therapies Market Revenues & Volume, By Clinics, 2021- 2031F |
7 China Intratumoral Cancer Therapies Market Import-Export Trade Statistics |
7.1 China Intratumoral Cancer Therapies Market Export to Major Countries |
7.2 China Intratumoral Cancer Therapies Market Imports from Major Countries |
8 China Intratumoral Cancer Therapies Market Key Performance Indicators |
8.1 Number of clinical trials and research studies conducted on intratumoral therapies in China |
8.2 Adoption rate of intratumoral therapies in major healthcare institutions |
8.3 Percentage of oncologists recommending intratumoral therapies to their patients |
8.4 Rate of approval of new intratumoral therapies by the Chinese regulatory authorities |
8.5 Patient satisfaction and outcomes following intratumoral cancer treatments |
9 China Intratumoral Cancer Therapies Market - Opportunity Assessment |
9.1 China Intratumoral Cancer Therapies Market Opportunity Assessment, By Technology, 2021 & 2031F |
9.2 China Intratumoral Cancer Therapies Market Opportunity Assessment, By Application, 2021 & 2031F |
9.3 China Intratumoral Cancer Therapies Market Opportunity Assessment, By End-users, 2021 & 2031F |
10 China Intratumoral Cancer Therapies Market - Competitive Landscape |
10.1 China Intratumoral Cancer Therapies Market Revenue Share, By Companies, 2024 |
10.2 China Intratumoral Cancer Therapies Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |